A retrospective analysis of clinical outcomes between hospitalized patients with COVID‐19 who received famotidine or pantoprazole

Wagner et al., JGH Open, doi:10.1002/jgh3.12905 (abstract 10/31/2021), Oct 2021

Famotidine for COVID-19

25th treatment shown to reduce risk in October 2021, now with p = 0.00072 from 29 studies, recognized in 2 countries.

No treatment is 100% effective.
Protocols combine treatments.

Retrospective 2,184 hospitalized patients in the USA, 638 treated with famotidine, showing lower mortality with treatment.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments. This may explain in part the very high mortality seen in this study. Results may differ in countries with improved SOC.
OutcomeImprovementEffect · pTreatmentControl
risk of death 64.5% lower · RR 0.36 · p < 0.001*** 64.5% lowerRR 0.36p < 0.001*** 82 of 638 (12.9%) 182 of 819 (22.2%) treatment 82 of 638 (12.9%), control 182 of 819 (22.2%)adjusted per studyodds ratio converted to relative riskmultivariable
risk of mechanical ventilation 6.4% lower · RR 0.94 · p = 0.77 6.4% lowerRR 0.94p = 0.77 48 of 638 (7.5%) 75 of 819 (9.2%) treatment 48 of 638 (7.5%), control 75 of 819 (9.2%)adjusted per studyodds ratio converted to relative riskmultivariable

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. *** p < 0.001

Wagner et al., 31 Oct 2021, retrospective, USA, peer-reviewed, 5 authors, study period 1 March, 2020 - 1 March, 2021. Contact: jj.wagner5492@gmail.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Gastrointestinal Symptoms and Association With Respiratory Symptoms in Patients Diagnosed With SARS-CoV 2 (COVID-19)
MD Ernesto Robalino Gonzaga, MD Irene Riestra Guiance, MD Richard Henriquez, MD Mahmoud Ibrahim, MD Yuya Nway, DO Minh Ho, Jane Ha, MD, PhD Yeongkeun Kwon, BS Dohyang Kim, PhD Jinseub Hwang, PhD Jin-Won Kwon, MD, PhD Sungsoo Park
Figure 1. Panel a: Hospitalized COVID-19 patients with GI Symptoms on Admission demographic characteristics and ICU or non ICU admissions comparing with presence or no of respiratory symptoms. Panel b: Odds Ratio Estimates for ICU Admission in Patients with COVID-19 presenting with GI symptoms.
DOI record: { "DOI": "10.1002/jgh3.12905", "ISSN": [ "2397-9070", "2397-9070" ], "URL": "http://dx.doi.org/10.1002/jgh3.12905", "alternative-id": [ "10.1002/jgh3.12905" ], "author": [ { "ORCID": "http://orcid.org/0000-0002-9519-4834", "affiliation": [ { "name": "Department of Medicine South Brooklyn Health Brooklyn New York USA" } ], "authenticated-orcid": false, "family": "Wagner", "given": "Justin J.", "sequence": "first" }, { "affiliation": [ { "name": "Department of Medicine South Brooklyn Health Brooklyn New York USA" } ], "family": "St. Cyr", "given": "Nikolas", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medicine South Brooklyn Health Brooklyn New York USA" } ], "family": "Douen", "given": "Aaron", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Business Management Brooklyn New York USA" } ], "family": "Fogel", "given": "Joshua", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medicine South Brooklyn Health Brooklyn New York USA" } ], "family": "Trillo", "given": "John", "sequence": "additional" } ], "container-title": "JGH Open", "container-title-short": "JGH Open", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2023, 7, 11 ] ], "date-time": "2023-07-11T04:44:46Z", "timestamp": 1689050686000 }, "deposited": { "date-parts": [ [ 2023, 7, 11 ] ], "date-time": "2023-07-11T04:45:09Z", "timestamp": 1689050709000 }, "indexed": { "date-parts": [ [ 2023, 7, 12 ] ], "date-time": "2023-07-12T04:27:09Z", "timestamp": 1689136029379 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2023, 7, 10 ] ] }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 7, 10 ] ], "date-time": "2023-07-10T00:00:00Z", "timestamp": 1688947200000 } } ], "link": [ { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/jgh3.12905", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "311", "original-title": [], "prefix": "10.1002", "published": { "date-parts": [ [ 2023, 7, 10 ] ] }, "published-online": { "date-parts": [ [ 2023, 7, 10 ] ] }, "publisher": "Wiley", "reference": [ { "key": "e_1_2_6_2_1", "unstructured": "World Health Organization. (2023).WHO Coronavirus Disease (COVID‐19) dashboard. Available from:https://covid19.who.int/Accessed 16 Jan 2023." }, { "article-title": "Clinical characteristics of COVID‐19 patients with digestive symptoms in Hubei, China", "author": "Pan L", "first-page": "1", "journal-title": "Am. J. Gastroenterol.", "key": "e_1_2_6_3_1", "volume": "115", "year": "2020" }, { "DOI": "10.1016/j.apsb.2020.02.008", "article-title": "Analysis of therapeutic targets for SARS‐CoV‐2 and discovery of potential drugs by computational methods", "author": "Wu C", "doi-asserted-by": "crossref", "first-page": "766", "journal-title": "Acta Pharm Sin. B.", "key": "e_1_2_6_4_1", "volume": "10", "year": "2020" }, { "article-title": "Mast cells contribute to coronavirus‐induced inflammation: new anti‐inflammatory strategy", "author": "Kritas SK", "first-page": "9", "journal-title": "J. Biol. Regul. Homeost. Agents", "key": "e_1_2_6_5_1", "volume": "34", "year": "2020" }, { "article-title": "Broad‐spectrum inhibition of coronavirus main and papain‐like proteases by HCV drugs", "author": "Anson BJ", "first-page": "10.21203/rs.3.r", "journal-title": "Res. Sq.", "key": "e_1_2_6_6_1", "year": "2020" }, { "DOI": "10.1126/science.abc4739", "doi-asserted-by": "crossref", "key": "e_1_2_6_7_1", "unstructured": "BorrellB.New York clinical trial quietly tests heartburn remedy against coronavirus. Available from:https://www.science.org/content/article/new-york-clinical-trial-quietly-tests-heartburn-remedy-against-coronavirus. Accessed 7 Nov 2021." }, { "DOI": "10.1053/j.gastro.2020.05.053", "article-title": "Famotidine use is associated with improved clinical outcomes in hospitalized COVID‐19 patients: a propensity score matched retrospective cohort study", "author": "Freedberg DE", "doi-asserted-by": "crossref", "first-page": "1129", "journal-title": "Gastroenterology", "key": "e_1_2_6_8_1", "volume": "159", "year": "2020" }, { "DOI": "10.14309/ajg.0000000000000832", "article-title": "Impact of famotidine use on clinical outcomes of hospitalized patients with COVID‐19", "author": "Mather JF", "doi-asserted-by": "crossref", "first-page": "1617", "journal-title": "Am. J. Gastroenterol.", "key": "e_1_2_6_9_1", "volume": "115", "year": "2020" }, { "article-title": "Association between famotidine use and COVID‐19 severity in Hong Kong: a territory‐wide study", "author": "Cheung KS", "first-page": "34940", "journal-title": "Gastroenterology", "key": "e_1_2_6_10_1", "volume": "0016", "year": "2020" }, { "DOI": "10.14309/ajg.0000000000001153", "article-title": "Comparative effectiveness of famotidine in hospitalized COVID‐19 patients", "author": "Shoaibi A", "doi-asserted-by": "crossref", "first-page": "692", "journal-title": "Am. J. Gastroenterol.", "key": "e_1_2_6_11_1", "volume": "116", "year": "2021" }, { "DOI": "10.1053/j.gastro.2020.10.011", "article-title": "Famotidine use is not associated with 30‐day mortality: a coarsened exact match study in 7158 hospitalized patients with coronavirus disease 2019 from a large healthcare system", "author": "Yeramaneni S", "doi-asserted-by": "crossref", "first-page": "919", "journal-title": "Gastroenterology", "key": "e_1_2_6_12_1", "volume": "160", "year": "2021" }, { "DOI": "10.1007/s10620-021-06872-z", "article-title": "Does famotidine reduce the risk of progression to severe disease, death, and intubation for COVID‐19 patients? A systemic review and meta‐analysis", "author": "Sun C", "doi-asserted-by": "crossref", "first-page": "3929", "journal-title": "Dig. Dis. Sci.", "key": "e_1_2_6_13_1", "volume": "66", "year": "2023" }, { "DOI": "10.1038/cddis.2016.218", "article-title": "Proton pump inhibitors protect mice from acute systemic inflammation and induce long‐term cross‐tolerance", "author": "Balza E", "doi-asserted-by": "crossref", "journal-title": "Cell Death Dis.", "key": "e_1_2_6_14_1", "volume": "7", "year": "2016" }, { "DOI": "10.1503/cmaj.092129", "article-title": "Use of acid‐suppressive drugs and risk of pneumonia: a systematic review and meta‐analysis", "author": "Eom CS", "doi-asserted-by": "crossref", "first-page": "310", "journal-title": "CMAJ", "key": "e_1_2_6_15_1", "volume": "183", "year": "2011" }, { "DOI": "10.1186/s12916-021-01907-8", "article-title": "Relation of severe COVID‐19 to polypharmacy and prescribing of psychotropic drugs: the REACT‐SCOT case‐control study", "author": "McKeigue PM", "doi-asserted-by": "crossref", "first-page": "51", "journal-title": "BMC Med.", "key": "e_1_2_6_16_1", "volume": "19", "year": "2021" }, { "DOI": "10.1097/MEG.0000000000002013", "article-title": "Pre‐hospitalization proton pump inhibitor use and clinical outcomes in COVID‐19", "author": "Ramachandran P", "doi-asserted-by": "crossref", "first-page": "137", "journal-title": "Eur. J. Gastroenterol. Hepatol.", "key": "e_1_2_6_17_1", "volume": "34", "year": "2022" }, { "article-title": "Severe clinical outcomes of COVID‐19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching", "author": "Lee SW", "first-page": "76", "journal-title": "Gut", "key": "e_1_2_6_18_1", "volume": "70", "year": "2020" }, { "DOI": "10.1111/joim.13183", "article-title": "Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID‐19: a meta‐analysis", "author": "Kow CS", "doi-asserted-by": "crossref", "first-page": "125", "journal-title": "J. Intern. Med.", "key": "e_1_2_6_19_1", "volume": "289", "year": "2021" }, { "DOI": "10.1136/gutjnl-2022-326952", "article-title": "Oral famotidine versus placebo in non‐hospitalised patients with COVID‐19: a randomised, double‐blind, data‐intense, phase 2 clinical trial", "author": "Brennan CM", "doi-asserted-by": "crossref", "first-page": "879", "journal-title": "Gut", "key": "e_1_2_6_20_1", "volume": "71", "year": "2022" }, { "DOI": "10.3389/fphar.2021.633680", "article-title": "COVID‐19: famotidine, histamine, mast cells, and mechanisms", "author": "Malone RW", "doi-asserted-by": "crossref", "journal-title": "Front. Pharmacol.", "key": "e_1_2_6_21_1", "volume": "12", "year": "2021" }, { "DOI": "10.1001/archinte.158.1.54", "article-title": "A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy", "author": "Lin HJ", "doi-asserted-by": "crossref", "first-page": "54", "journal-title": "Arch. Intern. Med.", "key": "e_1_2_6_22_1", "volume": "158", "year": "1998" }, { "DOI": "10.1136/bmj.38356.641134.8F", "article-title": "Systematic review and meta‐analysis of proton pump inhibitor therapy in peptic ulcer bleeding", "author": "Leontiadis GI", "doi-asserted-by": "crossref", "first-page": "568", "journal-title": "BMJ", "key": "e_1_2_6_23_1", "volume": "330", "year": "2005" }, { "DOI": "10.1016/j.transci.2020.102926", "article-title": "Anemia is associated with severe coronavirus disease 2019 (COVID‐19) infection", "author": "Hariyanto TI", "doi-asserted-by": "crossref", "journal-title": "Transfus. Apher. Sci.", "key": "e_1_2_6_24_1", "volume": "59", "year": "2020" }, { "DOI": "10.1001/jama.2019.22190", "article-title": "Effect of stress ulcer prophylaxis with proton pump inhibitors vs histamine‐2 receptor blockers on in‐hospital mortality among ICU patients receiving invasive mechanical ventilation", "author": "PEPTIC Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group, Alberta Health Services Critical Care Strategic Clinical Network, and the Irish Critical Care Trials Group", "doi-asserted-by": "crossref", "first-page": "616", "journal-title": "JAMA", "key": "e_1_2_6_25_1", "volume": "323", "year": "2020" }, { "DOI": "10.5414/CNP68065", "article-title": "Proton pump inhibitors and the kidney: critical review", "author": "Brewster UC", "doi-asserted-by": "crossref", "first-page": "65", "journal-title": "Clin. Nephrol.", "key": "e_1_2_6_26_1", "volume": "68", "year": "2007" }, { "DOI": "10.1159/000514940", "article-title": "Incidence and outcomes of acute kidney injury in COVID‐19: a systematic review", "author": "Raina R", "doi-asserted-by": "crossref", "first-page": "199", "journal-title": "Blood Purif.", "key": "e_1_2_6_27_1", "volume": "51", "year": "2022" }, { "DOI": "10.14309/01.ajg.0000715272.88349.c2", "article-title": "H2‐blocker use is associated with acute kidney injury among COVID‐19 patients", "author": "Trieu JA", "doi-asserted-by": "crossref", "first-page": "S1723", "journal-title": "Am. J. Gastroenter.", "key": "e_1_2_6_28_1", "volume": "115", "year": "2020" }, { "DOI": "10.1007/s00134-015-3725-1", "article-title": "Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients", "author": "Krag M", "doi-asserted-by": "crossref", "first-page": "833", "journal-title": "Intens. Care Med.", "key": "e_1_2_6_29_1", "volume": "41", "year": "2015" } ], "reference-count": 28, "references-count": 28, "relation": {}, "resource": { "primary": { "URL": "https://onlinelibrary.wiley.com/doi/10.1002/jgh3.12905" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Gastroenterology", "Hepatology" ], "subtitle": [], "title": "A retrospective analysis of clinical outcomes between hospitalized patients with <scp>COVID</scp>‐19 who received famotidine or pantoprazole", "type": "journal-article" }
Late treatment
is less effective